ON DEMAND WEBINAR
Duration: 1 hour​

Join us for an insightful webinar where we dive into the journey of Rimegepant, Biohaven Pharmaceutical’s innovative CGRP antagonist, designed for the treatment of migraines. This session will explore how clinical pharmacology, model-informed drug development (MIDD), and medical affairs were integrated across various phases of drug development, driving the success of Rimegepant. 

Participating in this discussion is Dr. Rick Bertz from BioHaven Pharmaceuticals, a seasoned expert in drug development, who will share his insights on establishing a framework for successful partnerships and strategies for optimizing drug development. The webinar will conclude with an engaging Q&A session, offering attendees the opportunity to dive deeper into these topics. Don't miss this opportunity to learn about the science and strategy behind the development of Rimegepant and how innovative drug development practices can optimize therapeutic success. Key topics include:

• Understanding the CGRP antagonist mechanism and its role in migraine therapy.
• A detailed look at Rimegepant’s early development, including the clinical pharmacology study with acid-reducing agents (ARA) and the development of a new salt formulation.
• How Physiologically Based Pharmacokinetic (PBPK) modeling was utilized to address the effects of ARAs on the new salt formulation.
• The impact of population PK modeling on Rimegepant’s development trajectory.
• The importance of medical writing and cross-functional collaboration to demonstrate thought leadership.

SPEAKERS

Raj Bhardwaj, PhD
Senior Director
Certara Drug Developement Solutions

Craig Comisar, PhD
Senior Director, Pharmacometrics
Certara Drug Developement Solutions

Amy Porter, PhD
Associate Principal Medical Writer
Certara Drug Developement Solutions

Rick Bertz, PhD
Senior Vice President, Clinical Pharmacology and Pharmacometrics
BioHaven Pharmaceuticals